Patent 8637516 was granted and assigned to IRM on January, 2014 by the United States Patent and Trademark Office.
The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated TRK kinase activity.